Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma (EUSRFAINSU)
Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies.
In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.
研究概览
详细说明
Patients (P): Alla patients referred to Sahlgrenska University Hospital for the diagnostic work-up and management of a suspected pancreatic insulinoma.
Intervention (I): EUS-RFA
Control group (C): Patients with insulinoma treated with conventional surgery during the time frame 2018-2025 (historic controls).
Outcome (O):
- Technical feasibility
- Patient safety
- Clinical efficacy (follow-up with biochemistry and imaging at 3, 6, 12, and 24 months post-EUS-RFA).
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Per Hedenström, Associate Professor
- 电话号码:+46 31 3421000
- 邮箱:per.hedenstrom@vgregion.se
研究联系人备份
- 姓名:Riadh Sadik, Associate Professor
- 电话号码:+46 31 3421000
学习地点
-
-
-
Gothenburg、瑞典
- 招聘中
- Sahlgrenska Univeristy Hospital
-
接触:
- Per Hedenström, Associate Professor
- 电话号码:+46 31 3421000
- 邮箱:per.hedenstrom@vgregion.se
-
接触:
- Riadh Sadik, Associate Professor
- 电话号码:+46 31 3421000
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Insulinoma verified by pathology (often from EUS-FNB-sampling)
Exclusion Criteria:
- Patients unwilling to participate
- Patients unable to understand and obtain written informed conscent
- Severe comorbidity
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Prospective cohort subjected to EUS-RFA
All patientens enrolled prospectively from 2025 and onwards subjected to EUS-RFA as treatemtn for pancreatic insulinoma
|
Treatment of insulinoma by EUS-RFA
|
|
Control group
All patients subjected to surgery due to insulinoma during 2018-2024 acting as a historic control group
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Clinical efficacy
大体时间:3-24 months post-EUS
|
Symptom-free survival after EUS-RFA (no clinical signs of residual disease, i.e. insulin-producing insulinoma cells)
|
3-24 months post-EUS
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Patient safety
大体时间:30 days post-EUS-RFA
|
Adverse evnt rate according to Clavien-Dindo at 30 days post-EUS-RFA
|
30 days post-EUS-RFA
|
|
Imaging effect post-EUS-RFA with respect to tumor size
大体时间:3-24 months post-EUS-RFA
|
Imaging of the insulinoma by EUS post-EUS-RFA and thereby the assessment of tumor size
|
3-24 months post-EUS-RFA
|
|
Imaging effect post-EUS-RFA with respect to tumor vascularization
大体时间:3-24 months post EUS-RFA
|
Imaging of the insulinoma by EUS post-EUS-RFA and thereby the assessment of remaining tumor vascularization
|
3-24 months post EUS-RFA
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.